Agustin Garcia ABRCC

    Clinical Researchers Showcase Series - February 2016

    Translational Medicine Research:

 View from the Trenches Newsletter

box_top.gif

Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted

only in a lab, to bedside clinical practice or dissemination

to population-based community interventions.

-  Source: NIH -- Read more


from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. Augustin Garcia, M.D.
Louisiana State University (LSU) School of Medicine, New Orleans, LA

ABRCC Investigator


Dr. Augustin Garcia is Section Chief and Professor, School of Medicine, Department of Medicine Hematology Oncology

 

Dr. Garcia specializes in the management of women's cancers (breast, ovary, uterus and cervix).  In addition to providing state of the art medical care to his patients, Dr. Garcia is committed to improving the prognosis and the quality of life of cancer patients and survivors while decreasing the toxicity and side effects associated with current treatments. Dr. Garcia's practice focuses not only in conventional medical therapies (chemotherapy, surgery and radiation) but follows instead a more integrative approach by introducing complementary medical therapies when indicated.

Dr. Garcia is originally from Mexico and earned his medical degree from Universidad Anahuac in Mexico City. He completed his internship and residency training in internal medicine at the University of Illinois and a fellowship in medical oncology at the University of Southern California. He is board certified in medical oncology. He had a fellowship at LAC+USC Medical Center in Medical Oncology, 1994 - 1997.  Dr. Garcia joined LSU in 2015 where he holds the Charles W McMullin III and Richard Paul Grace Chair in Cancer Research.

Dr. Garcia’s primary clinical and research interests focus on women’s cancers (particularly breast and ovarian cancers) and drug development. He is a member of the Breast Cancer Working Group in the Southwest Oncology Group and the Cervical Cancer Task Force from the Gynecologic Cancer Scientific Steering Committee of the National Cancer Institute.  He is also a member of several national and international organizations. His work has been published in various journals, such as the Journal of Clinical Oncology and Gynecologic Oncology. He is a frequent speaker at local, national and international events.

 

About LSU Health School of Medicine


Since its inception some 75 years ago, the school of medicine has maintained a deep commitment to serving all patients, particularly the underserved. We are aligned with the LSUHSC Health Care Services Division which consists of nine hospitals throughout the state. Through this important relationship, our faculty and house staff provide quality medical care to the residents of Louisiana regardless of income or insurance coverage. Simultaneously, our partnerships with the LSU Healthcare Network and local private hospitals supply outstanding care to a growing population of private patients. These wide ranging medical services support the people of our state while providing the backdrop for a broad and comprehensive clinical education for our students and residents in training.  In addition, LSU is home to the Stanley S. Scott Cancer Center (SSSCC) a multidisciplinary organization whose researchers and clinicians apply a range of expertise to cancer research, education, and patient care.  Learn more at  LSUHSC

box_bottom.gif

About the CONSORTIA MODEL 
for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.

 

To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.


The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website